Equities

Guizhou Sanli Pharmaceutical Co Ltd

603439:SHH

Guizhou Sanli Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)12.33
  • Today's Change0.40 / 3.35%
  • Shares traded10.05m
  • 1 Year change-23.98%
  • Beta1.2961
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments623631642
Total Receivables, Net687436365
Total Inventory1769889
Prepaid expenses6.476.744.14
Other current assets, total1.190.06--
Total current assets1,4931,1721,100
Property, plant & equipment, net615237158
Goodwill, net555162--
Intangibles, net23510720
Long term investments10130119
Note receivable - long term------
Other long term assets------
Total assets2,9201,8171,405
LIABILITIES
Accounts payable29517899
Accrued expenses424016
Notes payable/short-term debt255205200
Current portion long-term debt/capital leases450.50--
Other current liabilities, total20212445
Total current liabilities839549360
Total long term debt2540.170
Total debt555206200
Deferred income tax296.94--
Minority interest239(0.82)0.61
Other liabilities, total892313
Total liabilities1,450578374
SHAREHOLDERS EQUITY
Common stock410411411
Additional paid-in capital225230223
Retained earnings (accumulated deficit)877625424
Treasury stock - common(41)(27)(27)
Unrealized gain (loss)------
Other equity, total------
Total equity1,4701,2391,031
Total liabilities & shareholders' equity2,9201,8171,405
Total common shares outstanding405407407
Treasury shares - common primary issue5.093.543.54
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.